2C-B

Summary sheet: 2C-B

2C-B
Chemical Nomenclature
Common names	2C-B, Nexus, Bees
Substitutive name	4-Bromo-2,5-dimethoxyphenethylamine
Systematic name	2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine
Class Membership
Psychoactive class	Psychedelic
Chemical class	Phenethylamine
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. Oral Dosage Threshold Common Heavy 5 - 10 - 15 - 25 - 45 mg Light Strong Threshold 5 mg Light 10 - 15 mg Common 15 - 25 mg Strong 25 - 45 mg Heavy 45 mg + Duration Total 4 - 6 hours Onset 20 - 40 minutes Come up 40 - 60 minutes Peak 2 - 3 hours Offset 1.5 - 3 hours After effects 2 - 4 hours DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

4-Bromo-2,5-dimethoxyphenethylamine (also known as Nexus, Bromo Mescaline, BDMPEA, Venus, and 2C-B) is a lesser-known psychedelic substance of the phenethylamine class. It is the most popular member of the 2C-x family of psychedelic phenethylamines, all of which were derived from the systematic modification of the mescaline molecule.

2C-B was first synthesized in 1974 by Alexander Shulgin,^[1] and later documented in his 1991 book PiHKAL ("Phenethylamines I Have Known and Loved").^[2] It is a member of the so-called "magical half-dozen" which refers to Shulgin's self-rated most important phenethylamine compounds, all of which except mescaline he developed and synthesized himself.

2C-B first saw use in the underground psychiatric community as an adjunct in psychotherapy. It was considered one of the best substances for this purpose due to its short duration, relative absence of side effects, and comparably mild nature.^[3] It entered recreational usage shortly afterward and was sold commercially as an aphrodisiac^[4] under the trade name "Eros" and as tablets in Dutch smart shops under the name "Nexus" before becoming scheduled.^{[citation needed]}

Anecdotal reports describe the psychedelic effects of 2C-B as moderate, warm, and highly sensual. It is described as having a less serious or grandiose head space than LSD or psilocybin mushrooms, with a greater emphasis on visual and physical effects. Smaller doses are used as a sensory and aesthetic enhancer in a manner comparable to MDMA, while larger doses produce a distinct psychedelic effect. 2C-B is believed to be well-tolerated physiologically, with a safety profile similar to that of classical psychedelics.

History and culture

2C-B was first synthesized and explored by Alexander Shulgin in 1974. His findings were later published in his 1991 book PiHKAL, in which it was listed among the "magical half-dozen" of psychedelic phenethylamines that he deemed most important.^[5] The list consists of mescaline, DOM, 2C-B, 2C-E, 2C-T-2, and 2C-T-7.^[6] In interviews, Alexander Shulgin repeatedly declared it his favorite psychedelic trip.^[7]

In the 1970s, 2C-B was used in patients by a small number of psychotherapists in the United States. These therapists reported that it created a warm, empathetic bond between them and their patients. They also said the drug helped break down a patient's ego defenses and inner resistances, allowing the patient to get in touch with suppressed emotions and repressed memories.^[8] The gentle nature of 2C-B, in addition to its mild side effects and short duration, was found to be desirable traits for a therapeutic setting.

Not long after it gained traction in the medical community, 2C-B became popular in the recreational drug scene. 2C-B was well liked as a MDMA substitute in raves and parties due to its minimal comedown and a clear, euphoric headspace. In the 1980s and early 1990s, several foreign companies legitimately manufactured 2C-B under the brand names "Nexus", "Erox", and "Performax" and advertised that it would alleviate impotence, frigidity, and diminished libido. It was sold at adult book and video stores, "head" shops, and some nightclubs. The DEA reported its distribution in Miami, Florida as yellow pills marketed as an aphrodisiac.^{[citation needed]}

In the United States, 2C-B gained popularity as an alternative to MDMA after it was classified as a Schedule I drug in 1985. Its increasing popularity led it to be placed in Schedule I in 1995.^[9] It saw a resurgence in interest in the 2000s, with the advent of the research chemicals scene and darknet markets.

2C-B is used as entheogen by the Sangoma, Nyanga, and Amagqirha people over their traditional plants. It is referred to as Ubulawu Nomathotholo, which roughly translates to "Medicine of the Singing Ancestors".^[10]

Chemistry

2C-B, or 2,5-dimethoxy-4-bromophenethylamine, is a substituted phenethylamine. Substituted phenethylamines are a chemical class of organic compounds that are based upon the phenethylamine structure, a phenyl ring bound to an amino (NH₂) group through an ethyl chain. 2C-B possesses methoxy functional groups CH₃O- attached to carbons R₂ and R₅ as well as a bromine atom attached to carbon R₄ of the phenyl ring.

2C-B belongs to the 2C family of phenethylamines, all of which possess methoxy groups on the 2 and 5 positions of the benzene ring.^[11]

Pharmacology

Unlike most psychedelics, 2C-B has been shown to be a low efficacy serotonin 5-HT_2A receptor partial agonist^[12] or even full antagonist.^[13] This suggests that the 5-HT_2C receptor is primarily responsible for mediating the effects experienced by users of 2C-B.^[14] Research also suggests that 2C-B increases dopamine levels in the brains of rats which may contribute to its psychoactivity.^[15]

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Combinational effects

• Cannabis - Cannabis majorly intensifies and extends both the sensory and cognitive effects of 2C-B. Extreme caution should be exercised with this combination as it can also elevate the anxiety, confusion and psychosis risk of cannabis.
• Dissociatives - When combined with dissociatives, the geometry, euphoria, dissociation and hallucinatory effects are often greatly enhanced. Dissociative-induced holes, spaces, and voids while under the influence of 2C-B have significantly more vivid visuals than dissociatives alone. It also results in more intense internal hallucinations and corresponding confusion which can develop into delusions and psychosis.
• Nitrous - Nitrous oxide is commonly used in combination with psychedelics. The two are known to possess powerful cross-synergistic effects, including the capacity to send the user directly into an "ego death" state. The speed and intensity with which this occurs is very rapid and the euphoria that can result often leads to the urge to compulsively redose.
• MDMA - When combined with MDMA, the physical and cognitive effects of 2C-B become strongly amplified. The visual, physical and cognitive effects of 2C-B are also intensified with strong sensations of euphoric pleasure manifested through distinct body highs and headspaces, and uniquely colorful visuals. The synergy between these substances is unpredictable, and it is best to start with markedly lower dosages than one would take for both substances individually. This combination may increase the neurotoxic effects of MDMA based on its similarity to LSD, which has been found to increase MDMA neurotoxicity.^[16]
• Alcohol - Alcohol can increase the disinhibiting and euphoric effects of 2C-B which lends to its use in recreational settings. It can be used in light doses to "take the edge off" a trip as well as dull its psychedelic effects in a fashion somewhat similar to benzodiazepines. However, this is not typically recommended due to alcohol’s ability to cause dehydration and nausea and physical fatigue which can negatively affect a trip if taken in moderate to high dosages. Heavy drinking is strongly discouraged as it can easily lead to black outs and unpredictable behavior.
• Benzodiazepines - Benzodiazepines can, depending on the dosage, slightly to completely reduce the intensity of the cognitive, physical and visual effects of a 2C-B trip. They are very efficient at stopping "bad trips" at the cost of amnesia and reduced trip intensity. Caution is advised when acquiring them for this purpose due to their very high abuse and addiction potential.
• Psychedelics - When used in combination with other psychedelics, each substance's physical, cognitive and visual effects intensify and synergize strongly. The synergy between those substances is unpredictable, and for this reason generally not advised. If choosing to combine psychedelics, it is recommended to start with significantly lower dosages than one would take for either substance individually.

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

• Experience: 15mg 2C-B (oral) - A pleasant low-dose evening with Nexus
• Experience:150mg MDMA + 20mg 2C-B - I designed it this way myself

Additional experience reports can be found here:

• Erowid Experience Vaults: 2C-B

Toxicity and harm potential

The toxicity and long-term health effects of recreational 2C-B use do not seem to have been studied in any scientific context, and the exact toxic dose is unknown.

Anecdotal reports from those who have tried 2C-B suggest that there are no negative health effects attributed to simply trying it by itself at low to moderate doses or using it very sparingly (although nothing can be completely guaranteed).

It is strongly recommended that one use harm reduction practices when using this substance.

Lethal dosage

There is no current data for the LD₅₀ of 2C-B, but it is thought to be considerably higher than the active dose. Alexander Shulgin reported a 100 mg oral dose taken without apparent harm.^[17]

Tolerance and addiction potential

2C-B is non-addictive and the desire to use it can actually decrease with use.

Tolerance to the effects of 2C-B are not built almost immediately after ingestion as with other psychedelics. There are many anecdotal reports of people ingesting this substance many days in a row with no immediate tolerance build up.

Dangerous interactions

Although many psychoactive substances are safe to use on their own, they can become dangerous or even life-threatening when taken with other substances. The list below contains some potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses but still increase the possibility of injury of death. Independent research should always be conducted to ensure that a combination of two or more substances is safe before consumption.

• Lithium - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its glutaminergic and GABAergic effects.^{[citation needed]}
• Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.^{[citation needed]}
• Tramadol - Tramadol lowers the seizure threshold^[18] and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.^{[citation needed]}

Legal status

• Australia: 2C-B is illegal to possess, produce and sell in Australia.^{[citation needed]}
• Austria: 2C-B is illegal to possess, produce and sell in Austria under the SMG (Suchtmittelgesetz Österreich).^{[citation needed]}
• Belgium: 2C-B is illegal to possess, produce and sell in Belgium.^{[citation needed]}
• Brazil: 2C-B is illegal to possess, produce and sell in Brazil as it is listed on Portaria SVS/MS nº 344.^[19]
• Canada: 2C-B is a Schedule III drug in Canada.^[20]
• Croatia: 2C-B is illegal to possess, produce and sell in Croatia as a result of it being a 2,5-dimethoxyphenylethanamine.^[21]
• European Union: 2C-B is a Schedule II drug in the EU.^{[citation needed]}
• Italy: 2C-B is a Schedule I (tabella I) drug in Italy^[22]
• Estonia: 2C-B is a Schedule I drug in Estonia.^{[citation needed]}
• Finland: Possession, production and sale of 2C-B is illegal in Finland.^{[citation needed]}
• Germany: 2C-B is illegal to possess, produce and sell under the BtMG.^[23]
• Japan: Possession, production and sale is illegal.^{[citation needed]}
• The Netherlands: Possession, production and sale is illegal.^{[citation needed]}
• Latvia: 2C-B is a Schedule I controlled substance.^[24]
• Norway: 2C-B is a Schedule II drug.^{[citation needed]}
• Poland: 2C-B is a Schedule I drug.^{[citation needed]}
• Russia: Possession, production and sale is illegal.^{[citation needed]}
• Spain: 2C-B is a Category 2 drug.^{[citation needed]}
• Sweden: 2C-B is a Schedule I drug.^[25]
• Switzerland: Possession, production and sale is illegal.^[26]
• United Kingdom: 2C-B is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.^[27]
• United States: 2C-B is a Schedule I drug.^{[citation needed]}

See also

• Responsible use
• Psychedelic
• Phenethylamines
• 2C-x
• 2C-E
• 2C-B-FLY

External links

• 2C-B (Wikipedia)
• 2C-B (Erowid Vault)
• 2C-B (PiHKAL / Isomer Design)

Discussion

• The Big & Dandy 2C-B Thread - Stage 1 (Bluelight)
• 2C-B, broken down and described (Disregard Everything I Say)

Literature

• González, D., Torrens, M., & Farré, M. (2015). Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions. BioMed Research International, 2015. https://doi.org/10.1155/2015/643878
• Papaseit, E., Farré, M., Pérez-Mañá, C., Torrens, M., Ventura, M., Pujadas, M., ... & González, D. (2018). Acute Pharmacological Effects of 2C-B in Humans: An Observational Study. Frontiers in Pharmacology, 9, 206. https://doi.org/10.3389/fphar.2018.00206

References